Attorney Docket No.: UM-07269



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gary D. Glick

Serial No.:

09/767,283

Filed:

01/22/2001

Group No.:

1618

Examiner:

Kim, Vickie Y.

Entitled:

Therapeutic Application of Pro-Apoptotic Benzodiazepines

## **TRANSMITTAL**

**Mail Stop Amendments** 

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

### CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

Thereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, in the above-identified application, for filing in the U.S. Patent Office.

Applicants believe no fee is required. The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: November 29, 2006

Robert A/Goetz Registration No. 55,210

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 305 San Francisco, California 94105 608/218-6900



## NITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gary D. Glick

Serial No.:

09/767,283

01/22/2001

Group No.:

1618

Filed: Entitled:

Examiner: Therapeutic Application of Pro-Apoptotic Benzodiazepines

Kim, Vickie Y.

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: November 29, 2006

#### Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- US Patent Number 6,277,844 B1 issued on 08/21/2001 to Spector, et al
- G.B. Jones, et al., The Non-covalent Interaction of pyrrolo [2, 1-c] [1,4] benzodiazepine-5, 11-diones with DNA, Anti-Cancer Drug Design, 5:249-264 (1990)
- International Search Report from WO 03/015703 A3 Published on February 27, 2003.
- International Search Report from WO 2005/004988 A3 Published on January 20, 2005
- International Search Report from WO 00/66106 A3 Published on November 11, 2000

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these attations constitutes prior art.

Dated: November 29, 2006

Registration No. 55,210

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of the perwork Reduction of the persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form RESIDENT

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete il Known			
Application Number	09/767,283		
Filing Date	01/22/2001		
First Named Inventor	Gary Glick		
Art Unit	1618		
Examiner Name	Kim, Vickie Y.		
Attorney Docket Number	LIM-07269		

Complete if Known

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (F known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	<sup>US-</sup> 6,277,844	08/21/2001	Spector, et al	Whole Document	
		US-				
		US-				
		US-				
		US-				
•		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-	<b>1</b>			
		US-				
		US-				

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3 -</sup> Number <sup>4 -</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
	2	WO 03/015703 A3	02/27/2003	Glick, Gary D.	Whole Document	
	3	WO 2005/004988 A	01/20/2005	Glick, Gary D.	Whole Document	
	4	WO 00/66106 A3	11/09/2000	Glick, Gary D.	Whole Document	
						<u> </u>
	ļ					<u> </u>
						1

Examiner		Date	
Signature		Considered	
g		000.00.00	1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	09/767,283	
INFORMATION DISCLOSURE	Filing Date	11/08/2001	
STATEMENT BY APPLICANT	First Named Inventor	Gary D. Glick	
(Use as many sheets as necessary)	Art Unit	1618	
(ose as many sneeds as necessary)	Examiner Name	Kim, Vickie Y.	
Sheet 2 of 2	Attorney Docket Number	UM-07269	

	NON PATENT LITERATURE DOCUMENTS	
Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
5	Jones, "The non-conalent interaction of pyrrolo[2, 1-c][benzodiazepines-5, 11-diones with DNA, Anti-Cancer Drug Design, 5:249-264 (1990)	
1	Date	
	No. <sup>1</sup>	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Jones, "The non-conalent interaction of pyrrolo[2, 1-c][benzodiazepines-5, 11-diones with DNA, Anti-Cancer Drug Design, 5:249-264 (1990)

		 _
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.